Traditional drug discovery is expensive, inefficient, and has huge barriers to entry. Big pharmaceutical companies continue to struggle to cope...

A quick scan of recent advances in the scientific community will show that genomic data and new techniques in next-gen sequencing have been gaining...

This is the third and final post of a series (part 1 and part 2) on directed evolution. What do protein engineers actually produce using directed...

Three outstanding examples for fragment-based drug discovery A good example for the reliability of the fragment-based screening method is the...

Directed evolution is emerging as a powerful new tool to design proteins with new and interesting properties that may not have evolved naturally...

Illumina recently announced the $1000 solution for the sequencing of the human genome in the form of its new instrument, the HiSeqX. This system...

The selection and accumulation of desirable mutations – also known as natural selection – has shaped the living world. The proteins resulting from...

One major challenge in drug discovery is determining whether a drug is behaving as intended, binding the “right” protein, inhibiting the correct...

This is Part 3 in a three-part series on Big Data in the pharma and biotech industries. (Check out Part 1 and Part 2). Big Data — the vast amount...

Incretins are hormones that the body uses to stimulate insulin release when nutrients are ingested. The two that are the most well-studied are...